Monopoly pricing of an antibiotic subject to bacterial resistance

Journal of Health Economics

Volumn 29, Issue 1, 2010, Pages 137-150

  Herrmann, Markus ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Antibiotic efficacy; Monopoly pricing; Patent length; Public health; Turnpike

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTICS; DISEASE TRANSMISSION; DRUGS TRADE; MONOPOLY; PHARMACEUTICAL INDUSTRY; PRICE DYNAMICS; PRICING POLICY; PUBLIC HEALTH;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; MATHEMATICAL MODEL; MONOPOLY PRICING; PATENT; PROSPECTIVE PRICING;

ANTI-BACTERIAL AGENTS; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; ECONOMIC COMPETITION; MODELS, ECONOMIC; PATENTS AS TOPIC; PUBLIC HEALTH;

BACTERIA (MICROORGANISMS);

EID: 77049089945     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2009.11.007     Document Type: Article

References (18)

1. Bonhoeffer S., Lipsitch M., Levin B.R. Evaluating treatment protocols to prevent antibiotic resistance. Proceedings of the National Academy of Sciences of the USA 1997, 94(22):12106-12111.
2. Coast J., Smith R.D., Millar M.R. An economic perspective on policy to reduce antimicrobial resistance. Social Science and Medicine 1998, 46:29-38.
3. Fischer C., Laxminarayan R. Sequential development and exploitation of an exhaustible resource: do monopoly rights promote conservation?. Journal of Environmental Economics and Management 2005, 49:500-515.
4. Gersovitz M., Hammer J.S. The economic control of infectious diseases. Economic Journal 2004, 114:1-27.
5. Herrmann M., Gaudet G. The economic dynamics of antibiotic efficacy under open access. Journal of Environmental Economics and Management 2009, 57:334-350.
6. Horowitz J.B., Moehring H.B. How property rights and patents affect antibiotic resistance. Health Economics 2004, 13:575-583.
7. Judd K.L. Numerical Methods in Economics 1998, MIT Press, Cambridge, MA.
8. Kessing S.G., Nuscheler R. Monopoly pricing with negative network effects: the case of vaccines. European Economic Review 2006, 50:1061-1069.
9. Kingston W. Antibiotics, invention and innovation. Research Policy 2000, 29:679-710.
10. Laxminarayan R., Brown G.M. Economics of antibiotic resistance: a theory of optimal use. Journal of Environmental Economics and Management 2001, 42:183-206.
11. Levy S.B. The Antibiotic Paradox 1992, Plenum Press, New York and London.
12. Mechoulan S. Market structure and communicable diseases. Canadian Journal of Economics 2007, 40:468-492.
13. Rudholm N. Economic implications of antibiotic resistance in a global economy. Journal of Health Economics 2002, 21:1071-1083.
14. Rowthorn, R., Brown, G.M., 2003. Using antibiotics when resistance is renewable, In: Laxminarayan, R. (Ed.), Battling Resistance to Antibiotics and Pesticides: An Economic Approach. Resources for the Future, Washington, DC, pp. 42-62.
15. Scott Morton, Fiona M. Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization 2000, 18:1085-1104.
16. Tisdell C. Exploitation of techniques that decline in effectiveness. Public Finance 1982, 37:428-437.
17. US Congress, Office of Technology Assessment, 1995. Impacts of antibiotic resistant bacteria: A report to the US Congress, (OTA-H-629). US Government Printing Office, Washington, DC.
18. Wilen, J.E., Msangi, S., 2003. Dynamics of antibiotic use: ecological versus interventionist strategies to manage resistance to antibiotics. In: Laxminarayan, R. (Ed.), Battling Resistance to Antibiotics and Pesticides: An Economic Approach. Resources for the Future, Washington, DC, pp. 17-41.